AAV-GAD gene for rat models of neuropathic pain and Parkinson's disease.

J. Kim, Y. S. Yoon, H. Lee, JinWoo Chang

Research output: Contribution to journalReview article

Abstract

The introduction of therapeutic genes to neurons by genetic modification has potential as an effective treatment for CNS disorders for all that a successful clinical application has not yet been fully implemented. In this paper, we will discussed the role of AAV vectors with the GAD65 gene for animal models of PD and neuropathic pain. AAV vector is one of the most attractive gene delivery vehicles for direct introduction of therapeutic genes into the CNS in the treatment of neurological diseases. GAD65 is present as a membrane-associated form in synapses and is primarily involved in producing synaptic gamma-aminobutyric acid (GABA) for vesicular release. We constructed rAAV-GAD65 expressing rat GAD65 and demonstrated that rat Parkinsonian symptoms can be significantly improved concomitantly with the production of GAD65. We also demonstrated rAAV-GAD65 as a successful gene delivery vehicle in a chronic pain model by administrating rAAV-GAD65 to DRGs because GABA driven by GAD is a major inhibitory neurotransmitter in the dorsal horn of the spinal cord and also plays an important role in the ventral horn. We believe that AAV vectors can be excellent candidates for gene therapy of neurological diseases.

Original languageEnglish
Pages (from-to)99-105
Number of pages7
JournalActa neurochirurgica. Supplement
Volume101
DOIs
Publication statusPublished - 2008 Sep 26

Fingerprint

Neuralgia
Parkinson Disease
Genes
gamma-Aminobutyric Acid
Diagnosis-Related Groups
Therapeutics
Horns
Chronic Pain
Genetic Therapy
Synapses
Neurotransmitter Agents
Animal Models
Neurons
Membranes

All Science Journal Classification (ASJC) codes

  • Surgery
  • Clinical Neurology

Cite this

@article{42ed520c04b44750bc67832cc26cf925,
title = "AAV-GAD gene for rat models of neuropathic pain and Parkinson's disease.",
abstract = "The introduction of therapeutic genes to neurons by genetic modification has potential as an effective treatment for CNS disorders for all that a successful clinical application has not yet been fully implemented. In this paper, we will discussed the role of AAV vectors with the GAD65 gene for animal models of PD and neuropathic pain. AAV vector is one of the most attractive gene delivery vehicles for direct introduction of therapeutic genes into the CNS in the treatment of neurological diseases. GAD65 is present as a membrane-associated form in synapses and is primarily involved in producing synaptic gamma-aminobutyric acid (GABA) for vesicular release. We constructed rAAV-GAD65 expressing rat GAD65 and demonstrated that rat Parkinsonian symptoms can be significantly improved concomitantly with the production of GAD65. We also demonstrated rAAV-GAD65 as a successful gene delivery vehicle in a chronic pain model by administrating rAAV-GAD65 to DRGs because GABA driven by GAD is a major inhibitory neurotransmitter in the dorsal horn of the spinal cord and also plays an important role in the ventral horn. We believe that AAV vectors can be excellent candidates for gene therapy of neurological diseases.",
author = "J. Kim and Yoon, {Y. S.} and H. Lee and JinWoo Chang",
year = "2008",
month = "9",
day = "26",
doi = "10.1007/978-3-211-78205-7_17",
language = "English",
volume = "101",
pages = "99--105",
journal = "Acta Neurochirurgica, Supplement",
issn = "0065-1419",
publisher = "Springer Wien",

}

AAV-GAD gene for rat models of neuropathic pain and Parkinson's disease. / Kim, J.; Yoon, Y. S.; Lee, H.; Chang, JinWoo.

In: Acta neurochirurgica. Supplement, Vol. 101, 26.09.2008, p. 99-105.

Research output: Contribution to journalReview article

TY - JOUR

T1 - AAV-GAD gene for rat models of neuropathic pain and Parkinson's disease.

AU - Kim, J.

AU - Yoon, Y. S.

AU - Lee, H.

AU - Chang, JinWoo

PY - 2008/9/26

Y1 - 2008/9/26

N2 - The introduction of therapeutic genes to neurons by genetic modification has potential as an effective treatment for CNS disorders for all that a successful clinical application has not yet been fully implemented. In this paper, we will discussed the role of AAV vectors with the GAD65 gene for animal models of PD and neuropathic pain. AAV vector is one of the most attractive gene delivery vehicles for direct introduction of therapeutic genes into the CNS in the treatment of neurological diseases. GAD65 is present as a membrane-associated form in synapses and is primarily involved in producing synaptic gamma-aminobutyric acid (GABA) for vesicular release. We constructed rAAV-GAD65 expressing rat GAD65 and demonstrated that rat Parkinsonian symptoms can be significantly improved concomitantly with the production of GAD65. We also demonstrated rAAV-GAD65 as a successful gene delivery vehicle in a chronic pain model by administrating rAAV-GAD65 to DRGs because GABA driven by GAD is a major inhibitory neurotransmitter in the dorsal horn of the spinal cord and also plays an important role in the ventral horn. We believe that AAV vectors can be excellent candidates for gene therapy of neurological diseases.

AB - The introduction of therapeutic genes to neurons by genetic modification has potential as an effective treatment for CNS disorders for all that a successful clinical application has not yet been fully implemented. In this paper, we will discussed the role of AAV vectors with the GAD65 gene for animal models of PD and neuropathic pain. AAV vector is one of the most attractive gene delivery vehicles for direct introduction of therapeutic genes into the CNS in the treatment of neurological diseases. GAD65 is present as a membrane-associated form in synapses and is primarily involved in producing synaptic gamma-aminobutyric acid (GABA) for vesicular release. We constructed rAAV-GAD65 expressing rat GAD65 and demonstrated that rat Parkinsonian symptoms can be significantly improved concomitantly with the production of GAD65. We also demonstrated rAAV-GAD65 as a successful gene delivery vehicle in a chronic pain model by administrating rAAV-GAD65 to DRGs because GABA driven by GAD is a major inhibitory neurotransmitter in the dorsal horn of the spinal cord and also plays an important role in the ventral horn. We believe that AAV vectors can be excellent candidates for gene therapy of neurological diseases.

UR - http://www.scopus.com/inward/record.url?scp=52249099713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52249099713&partnerID=8YFLogxK

U2 - 10.1007/978-3-211-78205-7_17

DO - 10.1007/978-3-211-78205-7_17

M3 - Review article

C2 - 18642642

VL - 101

SP - 99

EP - 105

JO - Acta Neurochirurgica, Supplement

JF - Acta Neurochirurgica, Supplement

SN - 0065-1419

ER -